Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yasuhisa Nagasaka"'
Autor:
Masato Ohbuchi, Mayu Shibuta, Kazuhiro Tetsuka, Haruna Sasaki-Iwaoka, Masayo Oishi, Fumitaka Shimizu, Yasuhisa Nagasaka
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6496 (2024)
Blood–brain barrier (BBB) dysfunction is a key feature in neuroimmunological and neurodegenerative diseases. In this study, we developed a microfluidic human BBB-on-a-chip to model barrier dysfunction and immune cell migration using immortalized TY
Externí odkaz:
https://doaj.org/article/092c4504b13544d2ac8c2946f907717c
Autor:
Hiroyuki Sayama, Diana Marcantonio, Takeyuki Nagashima, Masashi Shimazaki, Tsuyoshi Minematsu, Joshua F Apgar, John M. Burke, Lucia Wille, Yasuhisa Nagasaka, Daniel C. Kirouac
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 864-877 (2021)
Abstract KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is a novel, highly potent, and se
Externí odkaz:
https://doaj.org/article/307d52ab94554a9cbf4a9e35c1594f22
Autor:
Rie Yamamoto, Youhei Okada, Jun Hirose, Tadatsura Koshika, Yuka Kawato, Masashi Maeda, Rika Saito, Kazuyuki Hattori, Hironori Harada, Yasuhisa Nagasaka, Tatsuaki Morokata
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e110819 (2014)
Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid that acts through the members of a family of five G protein-coupled receptors (S1P1-S1P5). S1P1 is a major regulator of lymphocyte trafficking, and fingolimod, whose active metabolit
Externí odkaz:
https://doaj.org/article/237719e5f8af4bd3b995d13d085e28fd
Autor:
Takeyuki Nagashima, Diana H. Marcantonio, Tsuyoshi Minematsu, Daniel C. Kirouac, Masashi Shimazaki, John M. Burke, Yasuhisa Nagasaka, Joshua F. Apgar, Hiroyuki Sayama, Lucia Wille
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 864-877 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRAS G12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is a novel, highly potent, and selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4404b4285eefa28947f77b57ba1c5fa2
https://doi.org/10.1002/psp4.12661
https://doi.org/10.1002/psp4.12661
Publikováno v:
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 154(3)
Quantitative systems pharmacology (QSP) is an emerging field of modeling technologies that describes the dynamic interaction between biological systems and drugs. Recently, QSP is increasingly being applied to pharmaceutical drug discovery and develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb5c2736af69d4c27d80cff7c948e812
https://pubmed.ncbi.nlm.nih.gov/31527365
https://pubmed.ncbi.nlm.nih.gov/31527365
Publikováno v:
Biopharmaceuticsdrug disposition. 40(5-6)
We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef46abce8e3b7794e84b20e0a76e338a
https://pubmed.ncbi.nlm.nih.gov/30985942
https://pubmed.ncbi.nlm.nih.gov/30985942
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(8)
This was the first study to construct a physiologically-based pharmacokinetic (PBPK) model for mirabegron which incorporates the overall elimination pathways of metabolism by cytochrome P450 (CYP) 3A4, uridine 5'-diphosphate-glucuronosyltransferase (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b1abc62176d11ab52aacff190c4c45b
https://pubmed.ncbi.nlm.nih.gov/30301385
https://pubmed.ncbi.nlm.nih.gov/30301385
Autor:
Yasuhisa Nagasaka, Ogert Fisniku, Taiji Sawamoto, Kazuo Oda, Ying J Cao, Naoyuki Nakada, Kinya Yamanouchi Pharmaceutical Co. Ltd. Sohda
Publikováno v:
Xenobiotica. 45:887-902
1. The human mass balance of 14C-labelled ASP015K ([14C]ASP015K), an orally bioavailable Janus kinase (JAK) inhibitor, was characterized in six healthy male subjects after a single oral dose of [14C]ASP015K (100 mg, 3.7 MBq) in solution. [14C]ASP015K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adb790f97305167c4f457eea05fb55d0
https://doi.org/10.3109/00498254.2015.1026864
https://doi.org/10.3109/00498254.2015.1026864
Publikováno v:
Xenobiotica. 44:926-932
1. We investigated how deficiencies in P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) affect the pharmacokinetics of atypical antipsychotics aripiprazole and its active metabolite (dehydroaripiprazole) using normal Friend leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe18c9d792542368d6a945646a5344cd
https://doi.org/10.3109/00498254.2014.901585
https://doi.org/10.3109/00498254.2014.901585
Publikováno v:
Biopharmaceutics & Drug Disposition. 35:135-144
In this study, an in vitro experimental system for evaluating the inhibitory effect of investigational drugs on the P-glycoprotein (P-gp, MDR1)-mediated transport of tacrolimus (FK506) was developed using LLC-PK1-MDR1 and LLC-PK1 wild-type (control)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e00824e747026a8c11afb6d3ca46c0c
https://doi.org/10.1002/bdd.1876
https://doi.org/10.1002/bdd.1876